Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA-DPA3 is classified as a pseudogene within the human major histocompatibility complex (MHC) class II region, specifically mapped between HLA-DRA and HLA-DPA3 on chromosome 6[3]. Unlike other class II molecules (such as HLA-DR, HLA-DQ, HLA-DP functional alpha and beta chains) that present peptide antigens to T cells as part of the adaptive immune response, HLA-DPA3 does not encode a functional protein and has no known biological activity[1]. There are no known roles in disease, no drug interactions, and it is not considered a valid therapeutic or diagnostic target. This entry may arise from confusion with other functional HLA-DP alpha genes (such as HLA-DPA1), which are truly involved in immune presentation[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major histocompatibility complex, class II, DP alpha 3 (pseudogene) (HLA-DPA3).